Collaboration Research Projects

The Hepatology Centre at the University of Berne is nationally and internationally present and participates actively in various collaborative projects:

The Swiss Hepatitis C Cohort has been gathering prospective data and biological samples from patients with Hepatitis C for more than 10 years. This cohort attracted worldwide attention because it formed the basis for important information such as the role of IL-28 (Interleukin 28) in the course of Chronic Hepatitis C.


VALDIG consortium is an independent network of researchers with a common interest in Vascular Liver Diseases. The aim of this network is to foster research in this field. All VALDIG centers are connected by one database, which allows for the coordination of joint research projects. In addition, VALDIG is supporting the establishment of new research groups to provide young researchers with the opportunity for interaction and knowledge building

Logo Valdig

The CLIF consortium is interested in the acute decompensation of patients with cirrhosis. This severe clinical course of the disease remains presently still inadequately understood. Therefore a wider knowledge of this disease is vitally necessary in order to improve the poor prognosis. The CLIF-Consortium in Europe was formed to this purpose. Drawing upon this data a new method of assessing (a new score) was developed, to establish a more accurate way of classifying and stratifying the patients.


The LITMUS Cohort is a European Cohort of patients with fatty liver. Fatty liver is a very common disease. A small proportion of patients with fatty liver can develop a steatohepatitis and, as a result, a liver cirrhosis. Together with our fellow members in Spain, Italy, Austria, France, Denmark and England we collect epidemiological data in patients with fatty liver.


Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint Undertaking, brings together clinicians and scientists from prominent academic centres across Europe with companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA). Their common goals are developing, validating and qualifying better biomarkers for testing NAFLD.



Involvement and contribution

Prof. Dr. med. J.-F. Dufour is or was a member of

in the function of an education councillor (council member).

(See also CV Prof. Dufour,  page 13).

Prof. Dr. med. J.-F. Dufour is or has been "Associated Editor" for these international journals


Prof. Dr. med. Berzigotti is member of the Scientific Committee of the Governing Board of the European Association for the Study of the Liver (EASL) as well as member of the Steering Committee of the Liver Forum, international collaborative research aimed at facilitating drug development for the treatment of liver disease

Prof. Dr. med. Andrea De Gottardi (EOC) is member of the Board of the Swiss Association for the Study of the Liver (SASL) and of the VALDIG consortium. Aside, he is Co-Founder of the Swiss Association for Liver Patients "swissHePa".